CAJ | 학술논문

恶性肿瘤患者应用细胞因子诱导的杀伤细胞治疗后不良反应分析
악성종류환자응용세포인자유도적살상세포치료후불량반응분석
Adverse reactions in patients with malignant tumor after treatment with cytokine-induced killer cells

万方数据

解放军医学院学报解放軍醫學院學報 해방군의학원학보
Academic Journal of Chinese Pla Medical School
2013年 6期 628-631 ,共4页

王津%江朝光%韩为东%王瑶%卢学春%刘洋%张宝和%王吉%张燕%丰恺超%张文英%陈美霞%汪宣驰

왕진%강조광%한위동%왕요%로학춘%류양%장보화%왕길%장연%봉개초%장문영%진미하%왕선치

细胞因子诱导的杀伤细胞%不良反应%细胞因子%淋巴细胞归巢細胞因子誘導的殺傷細胞%不良反應%細胞因子%淋巴細胞歸巢
세포인자유도적살상세포%불량반응%세포인자%림파세포귀소
cytokine-induced killer cells%adverse reaction%cytokine%lymphocytes homing

　　目的观察细胞因子诱导的杀伤细胞(cytokine-induced killer，CIK)治疗恶性肿瘤中出现的不良反应、不良反应出现的可能原因及针对性治疗措施。方法回顾分析2008年3月-2012年10月730例恶性肿瘤患者回输CIK细胞悬液后各种不良反应的临床表现、实验室检查结果、采取的治疗措施及分析可能的原因。结果 CIK细胞回输后的不良反应有：发热(6.85%)、皮疹(1.64%)、消化道不适(0.96%)、关节疼痛(0.41%)、类过敏样反应及溶瘤综合征(均为0.14%)、类全身炎症反应综合征样反应(0.68%)，除合并血压下降、严重过敏样反应及溶瘤综合征需对症处理外，余无需特殊处理。不良反应原因可能与CIK细胞的归巢特征及个体差异有关。结论此疗法是安全有效的过继免疫治疗方法，相关不良反应经积极对症处理后可恢复。
　　목적관찰세포인자유도적살상세포(cytokine-induced killer，CIK)치료악성종류중출현적불량반응、불량반응출현적가능원인급침대성치료조시。방법회고분석2008년3월-2012년10월730례악성종류환자회수CIK세포현액후각충불량반응적림상표현、실험실검사결과、채취적치료조시급분석가능적원인。결과 CIK세포회수후적불량반응유：발열(6.85%)、피진(1.64%)、소화도불괄(0.96%)、관절동통(0.41%)、류과민양반응급용류종합정(균위0.14%)、류전신염증반응종합정양반응(0.68%)，제합병혈압하강、엄중과민양반응급용류종합정수대증처리외，여무수특수처리。불량반응원인가능여CIK세포적귀소특정급개체차이유관。결론차요법시안전유효적과계면역치료방법，상관불량반응경적겁대증처리후가회복。
Objective To study the causes and countermeasures of adverse reactions in patients with malignant tumor after treatment with cytokine-induced killer (CIK) cells. Methods Clinical manifestations, laboratory findings, treatment measures and causes of adverse reactions in 730 patients with malignant tumor after treated with CIK cells from March 2008 to October 2012 were retrospectively analyzed. Results The main adverse reactions after infusion of CIK cells were fever(6.85%), rash(1.64%), digestive discomfort(0.96%), arthralgia (0.41%), anaphylactoid reaction (0.14%), tumor lysis syndrome (0.14%), and systemic inflammatory response syndrome reaction (0.68%). All the side effects were not specifically treated except for hypotension, severe anaphylactoid reaction and tumor lysis syndrome. The adverse reactions were related with the homing characteristics of CIK cells and individual difference. Conclusion CIK cells therapy is a safe and effective adoptive immunotherapy for malignant tumor and its adverse reactions can be treated expectantly.